Biofrontera (BFRI) Reports Prelim Q3 Revenue of $8.7-$9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St set to open higher after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Biofrontera Inc. Announces Preliminary Third Quarter Revenues
October 4, 2023 8:33 AM EDTRevenues Increased 101% to 108% Over the Prior-Year Quarter
Affirms Guidance for Full-Year Revenue Growth of at Least 25% over 2022
WOBURN, MA / ACCESSWIRE / October 4, 2023 / Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced preliminary unaudited revenues for the three months ended September 30, 2023.
Revenues for the third quarter of 2023 are anticipated to be in the range of approximately $8.7 million to $9.0 million, an increase of approximately 101% to 108% compared with the third quarter of 2022. As a result,... More
